Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

Hungria V, et al.
New England Journal of Medicine
June 2024
Authors and Affiliates
V. Hungria, P. Robak, M. Hus, V. Zherebtsova, C. Ward, P.J. Ho, A.C. Ribas de Almeida, R. Hajek, K. Kim, S. Grosicki, H. Sia, A. Bryant, M. Pitombeira de Lacerda, G. Aparecida Martinez, A.M. Sureda Balarí, I. Sandhu, C. Cerchione, P. Ganly, M. Dimopoulos, C. Fu, M. Garg, A.-O. Abdallah, A. Oriol, M.E. Gatt, M. Cavo, R. Rifkin, T. Fujisaki, M. Mielnik, N. Pirooz, A. McKeown, S. McNamara, X. Zhou, M. Nichols, E. Lewis, R. Rogers, H. Baig, L. Eccersley, S. Roy‑Ghanta, J. Opalinska, and M.-V. Mateos, for the DREAMM-7 Investigators Clinica São Germano (V.H.) and Hospital das Clínicas and Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo (G.A.M.), São Paulo, Centro de Pesquisa e Ensino em Saúde de Santa Catarin, Florianópolis (A.C.R.A.), and Universidade da Região de Joinville and Centro de Hematologia e Oncologia, Joinville (M.P.L.) — all in Brazil; Medical University of Lodz, Lodz (P.R.), Medical University of Lublin, Lublin (M.H., M.M.), and the Medical University of Silesia, Katowice (S.G.) — all in Poland; Gorodskaya Klinicheskaya Bol’nitsa Imeni Saint Petersburg Botkina, Moscow (V.Z.); the Royal North Shore Hospital (C.W.) and Liverpool Hospital (A.B.), Sydney, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and Pindara Private Hospital, Gold Coast, QLD (H.S.) — all in Australia; the Department of Hematooncology, University Hospital Ostrava, and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic (R.H.); Sungkyunkwan University and Samsung Medical Center, Seoul, South Korea (K.K.); Institut Català d’Oncologia–L’Hospitalet de Llobregat–Barcelona, Barcelona (A.M.S.B.), Institut Català d’Oncologia and Josep Carreras Research Institute, Hospital Germans Trias i Pujol, Badalona (A.O.), and Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cáncer, Ciberonc, Salamanca (M.-V.M.) — all in Spain; Cross Cancer Institute, Edmonton (I.S.), and GSK, Mississauga (H.B.) — both in Canada; the Hematology Unit, Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori,” IRST IRCCS, Meldola (C.C.), and IRCCS Azienda Ospedaliero–Universitaria di Bologna, Istituto di Ematologia “Seràgnoli,” Bologna (M.C.) — both in Italy; Christchurch Hospital, Christchurch, New Zealand (P.G.); National and Kapodistrian University of Athens, Athens (M.D.); the First Affiliated Hospital of Soochow University, Suzhou, China (C.F.); University Hospitals of Leicester NHS Trust, Leicester (M.G.), GSK, Stevenage (A.M., S.M.), and GSK, London (L.E.) — all in the United Kingdom; University of Kansas Cancer Center, Fairway (A.-O.A.); the Department of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel (M.E.G.); Rocky Mountain Cancer Centers–Denver–Midtown, Denver (R. Rifkin); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); GSK, Upper Providence, PA (N.P., X.Z., R. Rogers, S.R.-G., J.O.); and GSK, Durham (M.N.), and GSK, Research Triangle Park (E.L.) — both in North Carolina

Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant

Derman B, et al.
Blood Cancer Journal
May 2024
Authors and Affiliates
Benjamin A. Derman1, Jennifer Cooperrider1, Jacalyn Rosenblatt2, David E. Avigan2, Murtuza Rampurwala1, David Barnidge3, Ajay Major 4, Theodore Karrison5, Ken Jiang1, Aubrianna Ramsland1, Tadeusz Kubicki 1 and Andrzej J. Jakubowiak 1 1Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA. 2Beth Israel Deaconess Medical Center, Boston, MA, USA. 3The Binding Site Group, part of Thermo Fisher, Rochester, MN, USA. 4University of Colorado, Denver, CO, USA. 5Department of Public Health Sciences, University of Chicago, Chicago, IL, USA.

Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma

Touzeau C, et al.
Blood
May 2024
Authors and Affiliates
Cyrille Touzeau,1-3 Aurore Perrot,4 Cyrille Hulin,5 Salomon Manier,6 Margaret Macro,7 Marie-Lorraine Chretien,8 Lionel Karlin,9 Martine Escoffre,10 Caroline Jacquet,11 Mourad Tiab,12 Xavier Leleu,13 Herve Avet-Loiseau,4 Alexandra Jobert,14 Lucie Planche,14 Jill Corre,4 and Philippe Moreau1-3 1Service d’hématologie, Centre Hospitalier Universitaire (CHU) Hotel Dieu, Nantes, France; 2Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (CRCI2NA), INSERM, Centre National de la Recherche Scientifique (CNRS), Université d'Angers, Université de Nantes, Nantes, France; 3Site de Recherche Intégrée sur le Cancer (SIRIC) “Imaging and Longitudinal Investigations to Ameliorate Decision-making (ILIAD),” Institut National du Cancer-Direction Générale de l'Offre de Soins (INCA-DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM) 12558, Nantes-Angers, France; 4CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Université de Toulouse, Université Paul Sabatier (UPS), Service d’Hématologie, Toulouse, France; 5Service d’hématologie, Hopital Haut-Léveque, CHU de Bordeaux, Pessac, France; 6Maladies du Sang, CHRU de Lille, Lille, France; 7Service d’hématologie, CHU de Caen, Caen, France; 8Hématologie Clinique, CHU Dijon Bourgogne, Dijon, France; 9Hopital Lyon Sud, Pierre-Bénite, France; 10Service d’hématologie, CHU de Rennes, Rennes, France; 11Service d’hématologie, CHU de Nancy, Vandoeuvre-le` s-Nancy, France; 12Service d’hématologie, Centre Hospitalier Departemental, La Roche sur Yon, France; 13Service d’hématologie, CHU de Poitiers, Poitiers, France; and 14Département de recherche clinique, CHU Hotel Dieu, Nantes, France

French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry

Ferment B, et al.
British Journal of Haematology
May 2024
Authors and Affiliates
B. Ferment1,2 J. Lambert3 D. Caillot4,5 I. Lafon4 L. Karlin6 A. Lazareth6 C. Touzeau7 X. Leleu8 N. Moya8 S. Harel1,2 A. Perrot9 P. Bories9 L. Vincent10 S. Lamure11 M. Mohty12 F. Malard12 S. Manier13 I. Yakoub-Agha13 J.-M. Schiano De Colella14 G. Brisou14 A. Talbot1,2 O. Decaux15 R. Houot15 S. Le Gouill16,17 N. Bigot3 T. Facon13 J. Corre9 P. Moreau7 B. Arnulf1,2 1Department of Immuno-Hematology, Hôpital Saint Louis, APHP/Université Paris Cité, Paris, France 2Inserm U976 HIPI, Team 5: Lymphocyte Development and Lymphoid Disorders, Hôpital Saint Louis, Paris, France 3Biostatistics Department, Hôpital Saint Louis, APHP/Université Paris Cité, Paris, France 4Department of Hematology, Institut de Cancérologie de Bourgogne (ICB), Dijon, France 5Department of Hematology, Dijon University Hospital, Dijon, France 6Department of Hematology, Hospices Civils de Lyon, Lyon Sud University Hospital, Pierre-Benite, France 7Department of Hematology, Nantes University Hospital, Nantes, France 8Department of Oncology-Haematology and Cellular Therapy, Poitiers University Hospital, Poitiers, France 9Department of Hematology, IUCT Oncopole—Institut Universitaire du Cancer de Toulouse, Toulouse, France 10Department of Hematology, Montpellier University Hospital, Montpellier, France 11Department of Hematology, Centre Léon Bérard, Lyon, France 12Saint-Antoine Hospital, INSERM UMRs 938, Sorbonne University, Paris, France 13Department of Hematology, Lille Regional and University Hospital, Lille, France 14Department of Hematology, Institut Paoli Calmettes, Marseille, France 15Department of Hematology, Rennes University Hospital, Pontchaillou Hospital, Rennes, France 16Université Versailles Saint-Quentin, Versailles, France 17Department of Hematology, Institut Curie, Paris, France

How I Use Next Generation Sequencing-MRD to Plan Approach and Prevent Relapse after HCT for Children and Adults with ALL

Muffly L, et al.
Blood
May 2024
Authors and Affiliates
Lori Muffly (Stanford University, United States) Emily Liang (Fred Hutchinson Cancer Center, United States) J. Dolan (Huntsman Cancer Institute/Intermountain Primary Chlldren's Hospital, Spencer Fox Eccles School of Medicine, University of Utah, United States) Michael Pulsipher (Huntsman Cancer Institute/Intermountain Primary Chlldren's Hospital, Spencer Fox Eccles School of Medicine, University of Utah., United States)

Mass Spectrometry-Based Assessment of M-protein in Peripheral Blood DuringMaintenance Therapy in Multiple Myeloma

Kubicki T, et al.
Blood
May 2024
Authors and Affiliates
Tadeusz Kubicki,1,2 Dominik Dytfeld,2 David Barnidge,3 Dhananjay Sakrikar,3 Anna Przybyłowicz-Chalecka,2 Krzysztof Jamroziak,4 Paweł Robak,5 Jarosław Czyż,6 Agata Tyczyńska,7 Agnieszka Druzd-Sitek,8 Krzysztof Giannopoulos,9 Tomasz Wróbel,10 Adam Nowicki,2 Tomasz Szczepaniak,2 Anna Łojko-Dankowska,2 Magdalena Matuszak,2 Lidia Gil,2 Bartosz Puła,11 Łukasz Szukalski,6 Agnieszka Końska,11 Jan Maciej Zaucha,7 Jan Walewski,8 Damian Mikulski,5 Olga Czabak,12 Tadeusz Robak,5 Ken Jiang, 1 Jennifer H Cooperrider, 1 Andrzej J Jakubowiak,1,* and Benjamin A Derman1,* 1University of Chicago, Chicago, USA; 2 Poznań University of Medical Sciences, Poznan, Poland; 3The Binding Site, part of Thermo Fisher, Rochester, USA; 4 Medical University of Warsaw, Warsaw, Poland; 5Medical University of Łódź, Łódź, Poland; 6 Nicolaus Copernicus University in Toruń Ludwik Rydygier, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland; 7Medical University of Gdańsk, Gdańsk, Poland; 8 Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; 9 Department of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland; 10 Wrocław Medical University, Wrocław, Poland; 11 Institute of Hematology and Blood Transfusion, Warsaw; 12 Medical University of Lublin, Lublin, Poland

Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial

O'Donnell E, et al.
Lancet Haematology
April 2024
Authors and Affiliates
Elizabeth O’Donnell, Clifton Mo, Andrew J Yee, Omar Nadeem, Jacob Laubach, Jacalyn Rosenblatt, Nikhil Munshi, Shonali Midha, Diana Cirstea, Pavlina Chrysafi, Nora Horick, Paul G Richardson, Noopur Raje Massachusetts General Hospital Cancer Center, Boston, MA, USA (E O’Donnell MD, A J Yee MD, D Cirstea MD, N Horick MS, Prof N Raje MD); Dana-Farber Cancer Institute, Boston, MA, USA (E O’Donnell, C Mo MD, O Nadeem MD, J Laubach MD, Prof N Munshi MD, S Midha MD, Prof P G Richardson MD); Beth Israel Deaconess Medical Center, Boston, MA, USA (J Rosenblatt MD); Mount Auburn Hospital, Cambridge, MA, USA (P Chrysafi MD); Harvard Medical School, Boston, MA, USA (E O’Donnell, C Mo, A J Yee, O Nadeem, J Laubach, J Rosenblatt, N Munshi, Prof S Midha, D Cirstea, P G Richardson, Prof N Raje)

Large-scale statistical mapping of T-cell receptor β sequences to Human Leukocyte Antigens

H. Jabran Zahid, et al.
bioRxiv
Pre-Print
April 2024
Authors and Affiliates
H. Jabran Zahid 1, Ruth Taniguchi 2, Peter Ebert 2, I-Ting Chow 2, Chris Gooley 1, Jinpeng Lv 1, Lorenzo Pisani 1, Mikaela Rusnak 2,Rebecca Elyanow 2, Hiroyuki Takamatsu 3, Wenyu Zhou 2, Julia Greissl 1, Harlan Robins 2 and Jonathan M. Carlson 1; 1 Microsoft Research - 14820 NE 36th St, Redmond, WA 98052; 2 Adaptive Biotechnologies - 1165 Eastlake Ave E, Seattle, WA 98109; 3 Faculty of Transdisciplinary Sciences for Innovation, Institute of Transdisciplinary Sciences for Innovation/ Department of Hematology, Kanazawa University, Kakumamachi, Kanazawa, Ishikawa 920-1192, Japan.

Isatuximab in combination with carfilzomib anddexamethasone in 1q21þ patients with relapsed/refractorymultiple myeloma: Long‐term outcomes in the Phase 3 IKEMA study

Facon T, et al.
hematological oncology
February 2024
Authors and Affiliates
Thierry Facon1 | Philippe Moreau2 | Ivan Špicka3 | Kenshi Suzuki4 | Kwee Yong5 | Joseph Mikhael6 | Taro Fukao7 | Kamlesh Bisht7 | Nicole M. Armstrong8 | Sandrine Macé9 | Marie‐Laure Risse10 | Thomas Martin11 1Department of Hematology, Lille University Hospital, Lille, France 2Department of Hematology, University Hospital Hôtel‐Dieu, Nantes, France 3Department of Hematology, 1st Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic 4Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center, Tokyo, Japan 5Department of Haematology, University College Hospital, London, UK 6Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, Arizona, USA 7Sanofi, Global Oncology, Cambridge, Massachusetts, USA 8Sanofi, Global Medical Affairs, Cambridge, Massachusetts, USA 9Sanofi, Research and Development, Chilly‐ Mazarin, France 10Sanofi, Research and Development, Vitry‐ Sur‐Seine, France 11University of California San Francisco Medical Center, San Francisco, California, USA

Daratumumab in Myeloma Patients With Early or Late Relapse After Initial Therapy: Subgroup Analysis of CASTOR and POLLUX.

Spencer A, et al.
Blood Advances
January 2024
Authors and Affiliates
Andrew Spencer, Philippe Moreau, M V Mateos, Hartmut Goldschmidt, Kenshi Suzuki, Mark-David Levin, Pieter Sonneveld, Robert Z Orlowski, Sung-Soo Yoon, Saad Z Usmani, Katja C Weisel, Donna Reece, Tahamtan Ahmadi, Huiling Pei, Wendy Garvin Mayo, Xue Gai, Jodi Carey, J Blake Bartlett, Robin Carson, Meletios-Athanasios A Dimopoulos